Previous 10 | Next 10 |
Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q1 2021 Earnings Call Apr 29, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q1 2021 Earnings Call Transcript
NovoCure Limited (NVCR) Q1 2021 Earnings Conference Call April 29, 2021, 08:00 AM ET Company Participants Adam Daney - Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief Financial Officer Uri Weinberg - Chief Science Officer Pr...
Novocure (NVCR) shares are down 4.9% in premarket trading after the company delivered disappointing Q1 results.Novocure missed on both revenues and EPS.The company had a net loss of $4.1M in the quarter compared to net income of $4M in the prior-year period.Revenue of $134.7M, howev...
The following slide deck was published by NovoCure Limited in conjunction with their 2021 Q1 earnings call. For further details see: NovoCure Limited 2021 Q1 - Results - Earnings Call Presentation
NovoCure (NVCR): Q1 GAAP EPS of -$0.04 misses by $0.06.Revenue of $134.7M (+32.3% Y/Y) misses by $3.41M.There were 3,454 active patients at March 31, 2021, representing 12% growth compared to March 31, 2020, and 1% growth compared to December 31, 2020.Press Release For further details see: ...
Quarterly net revenues of $134.7 million with 80% gross margin Interim analysis for phase 3 pivotal LUNAR trial in non-small cell lung cancer concluded with favorable recommendation to continue the trial with reduced sample size Novocure (NASDAQ: NVCR) today reported...
NovoCure (NASDAQ:NVCR) is scheduled to announce Q1 earnings results on Thursday, April 29th, before market open.The consensus EPS Estimate is $0.01 and the consensus Revenue Estimate is $138.11M (+35.6% Y/Y).Over the last 1 year, NVCR has beaten EPS estimates 25% of the time and has beaten re...
Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) application to initiate the KEYNOTE-B36 trial, conducted in collaboration with MSD (Merck & Co., Inc., Kenilworth, NJ, USA). Novocure also...
On April 13, Novocure (NASDAQ: NVCR) stock jumped after the company received a green light to accelerate a pivotal phase 3 study. The investigation involves its medical device, Optune, to treat advanced-stage non-small-cell lung cancer (NSCLC). Optune is a portable device ...
Novocure (NASDAQ: NVCR) hasn't exactly been the kind of stock that fired up investors very much throughout most of 2021. That changed recently, though, with good news providing a huge catalyst for the stock. In this Motley Fool Live video recorded on April 14, 2021 , Motley ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...